

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 19, 2022

INMED PHARMACEUTICALS INC.  
(Exact Name of Company as Specified in Charter)

British Columbia  
(State or Other Jurisdiction  
of Incorporation)

001-39685  
(Commission File Number)

98-1428279  
(IRS Employer  
Identification No.)

InMed Pharmaceuticals Inc.  
Suite 310 - 815 W. Hastings Street,  
Vancouver, B.C.  
Canada

(Address of Principal Executive Offices)

V6C 1B4  
(Zip Code)

Company's telephone number, including area code: (604) 669-7207

Not applicable  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class         | Trading Symbol(s) | Name of each exchange on which registered |
|-----------------------------|-------------------|---|
| Common Shares, no par value | INM               | The Nasdaq Stock Market LLC               |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure.**

On September 19, 2022, the Company announced that will report financial results on Friday, September 23, 2022 for the fiscal year ended June 30, 2022.

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:

| <b>Exhibit No.</b> | <b>Description</b>  |
|--------------------|---|
| 99.1               | <a href="#">News release, dated September 19, 2022</a>  |
| 104                | Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INMED PHARMACEUTICALS INC.

Date: September 20, 2022

By: /s/ Eric A Adams  
Eric A Adam  
President & CEO



NASDAQ: INM

Suite 310-815 W. Hastings St.  
Vancouver, BC, Canada V6C 1B4  
Tel: +1.604.669.7207  
Email: [info@inmedpharma.com](mailto:info@inmedpharma.com)  
[www.inmedpharma.com](http://www.inmedpharma.com)

### **InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022**

Vancouver, BC – September 19, 2022 – **InMed Pharmaceuticals Inc.** (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results on Friday, September 23, 2022 for the fiscal year ended June 30, 2022.

#### **Conference Call & Webcast:**

Friday, September 23, 2022, at 10:00 AM Pacific Time, 01:00 PM Eastern Time  
Registration Link: <https://register.vevent.com/register/BIa76ceda464264b3cae0b5ddb6e76a511>  
Webcast Link: <https://edge.media-server.com/mmc/p/cnawzqhu>  
(Webcast replay available for 12 months)

To access the call by phone, please go to the registration link, and you will be provided with dial in details. To avoid delays, we encourage participants to register a day in advance or at a minimum 15 minutes before the start of the call.

The Company’s full financial statements and related MD&A for the fiscal year ended June 30, 2022, will be available at [www.inmedpharma.com](http://www.inmedpharma.com) and at [www.sedar.com](http://www.sedar.com).

**About InMed:** InMed Pharmaceuticals is a global leader in the research, development and manufacturing of rare cannabinoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. We also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, visit [www.inmedpharma.com](http://www.inmedpharma.com) and [www.baymedica.com](http://www.baymedica.com).

#### **Investor Contact:**

Colin Clancy  
Vice President, Investor Relations and Corporate Communications  
T: +1.604.416.0999  
E: [cclancy@inmedpharma.com](mailto:cclancy@inmedpharma.com)

#### **Cautionary Note Regarding Forward-Looking Information:**

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: reporting financial results and business updates for the fiscal year ended June 30, 2022, on September 23, 2022; being a leader in the research, development and manufacturing rare cannabinoids; clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs; having significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.